A dedicated team ensures our Respiratory tests continue to perform against circulating strains and all tests meet external quality standards

Why we routinely monitor respiratory viruses?

Respiratory viruses such as SARS-CoV-2 and Influenza A/B are continuously monitored by organisations such as World Health Organisation. Emergence of variants in circulation may impact diagnostic assay performance. The SpeeDx expert respiratory team performs rigorous in silico and in vitro monitoring to ensure our product’s continued performance.

Our SARS-CoV-2 assay detect all known circulating variants including Omicron and Delta, so you can have confident in your COVID-19 diagnostics.

In – silico surveillance

Our dedicated respiratory virus monitoring team perform systematic computer based phylogenetic analysis of our PlexPCR® respiratory products including:

  • Monthly, in silico analysis of primer sets in accordance with global recommendations, including Medicine & Healthcare products Regulatory Agency (MHRA)
  • Bi-annual monitoring of respiratory virus assays against global databases for all targets
  • Monitoring for emerging respiratory variants to inform new assay development

In – vitro assay performance monitoring

Our expert team includes dedicated applications specialists who routinely monitor the performance of our tests including PlexPCR® RespiVirus and PlexPCR® SARS-CoV-2. We regularly participate in external quality assurance (EQA) programs to assess the performance of all SpeeDx assays in-vitro. The summary on these EQA reports are available by request.

Want more data on our products?